Deanna L. Kroetz, PhD

Deanna L. Kroetz, PhD

Professor, Departments of Biopharmaceutical Sciences and Pharmacuetical Chemistry, UCSF

Phone: (415) 476-1159 (voice)
UCSF Box 2911, San Francisco, CA 94143-2911

View on UCSF Profiles

Cancer Center Membership

Program Member » Developmental Therapeutics


Ohio State University, Columbus, OH, B.S., 1985, Pharmacy
University of Washington, Seattle, WA, Ph.D., 1990, Pharmaceutics
National Cancer Institute, Bethesda, MD, 1990-1993, Drug Metabolism

Professional Experience

  • 1990-1991
    Intramural Research Training Award (IRTA) Fellow, Laboratory of Molecular Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD
  • 1991-1993
    Pharmacology Research Associate (PRAT) Fellow, Laboratory of Molecular Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD
  • 1993-2000
    Assistant Professor of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, San Francisco, CA
  • 1995-present
    UCSF Liver Center Member
  • 2000-2006
    Associate Professor of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, San Francisco, CA
  • 2000-present
    Institute for Human Genetics (formerly Program in Human Genetics) Member
  • 2003-present
    Vice Chair for Pharmacogenomics, Department of Biopharmaceutical Sciences, School of Pharmacy, University of California San Francisco, San Francisco, CA
  • 2006-present
    Professor of Biopharmaceutical Sciences and Pharmaceutical Chemistry (now the Department of Bioengineering and Therapeutic Sciences), School of Pharmacy, University of California San Francisco, San Francisco, CA
  • 2009-present
    UCSF Helen Diller Family Comprehensive Cancer Center Member

Honors & Awards

  • 1985
    Eli Lilly Co. Achievement Award
  • 1985
    Ohio State University Presidential Scholar
  • 1990
    Intramural Research Training Award Fellowship
  • 1991-1993
    Pharmacology Research Associate Fellowship
  • 1995
    Josephine Sitterle Failer Alumni Award, Ohio State University College of Pharmacy
  • 1996
    American Association of Pharmaceutical Sciences New Investigator Award in Pharmacokinetics, Pharmacodynamics and Drug Metabolism
  • 2002
    American Society for Clinical Pharmacology and Therapeutics Leon Goldberg Young Investigator Award
  • 2008
    Elected Fellow, American Association of Pharmaceutical Scientists

Selected Publications

  1. Barbarino JM, Kroetz DL, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for human leukocyte antigen B. Pharmacogenet Genomics. 2015 Apr; 25(4):205-21.
    View on PubMed
  2. Haenisch S, Zhao Y, Chhibber A, Kaiboriboon K, Do LV, Vogelgesang S, Barbaro NM, Alldredge BK, Lowenstein DH, Cascorbi I, Kroetz DL. SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients. Neurobiol Dis. 2015 May; 77:127-40.
    View on PubMed
  3. Chhibber A, Kroetz DL, Tantisira KG, McGeachie M, Cheng C, Plenge R, Stahl E, Sadee W, Ritchie MD, Pendergrass SA. Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics. 2014 Dec; 15(16):2025-48.
    View on PubMed
  4. Barbarino JM, Kroetz DL, Altman RB, Klein TE. PharmGKB summary: abacavir pathway. Pharmacogenet Genomics. 2014 May; 24(5):276-82.
    View on PubMed
  5. Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, Hicks JK, Wilkinson MR, Haas DW, Kroetz DL. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. Clin Pharmacol Ther. 2014 May; 95(5):499-500.
    View on PubMed
  6. Chhibber A, Mefford J, Stahl EA, Pendergrass SA, Baldwin RM, Owzar K, Li M, Winer EP, Hudis CA, Zembutsu H, Kubo M, Nakamura Y, McLeod HL, Ratain MJ, Shulman LN, Ritchie MD, Plenge RM, Witte JS, Kroetz DL. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). Pharmacogenomics J. 2014 Aug; 14(4):336-42.
    View on PubMed
  7. Nicol MR, Fedoriw Y, Mathews M, Prince HM, Patterson KB, Geller E, Mollan K, Mathews S, Kroetz DL, Kashuba AD. Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. J Clin Pharmacol. 2014 May; 54(5):574-83.
    View on PubMed
  8. Markova SM, Schwartz JB, Kroetz DL. Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers". Clin Pharmacol Ther. 2014 Mar; 95(3):252.
    View on PubMed
  9. Micheli JE, Chinn LW, Shugarts SB, Patel A, Martin JN, Bangsberg DR, Kroetz DL. Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes? Pharmacogenet Genomics. 2013 Nov; 23(11):591-6.
    View on PubMed
  10. Markova SM, Kroetz DL. ABCC4 is regulated by microRNA-124a and microRNA-506. Biochem Pharmacol. 2014 Feb 1; 87(3):515-22.
    View on PubMed
  11. Liu Y, Lu X, Nguyen S, Olson JL, Webb HK, Kroetz DL. Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway. Mol Pharmacol. 2013 Dec; 84(6):925-34.
    View on PubMed
  12. Motsinger-Reif AA, Jorgenson E, Relling MV, Kroetz DL, Weinshilboum R, Cox NJ, Roden DM. Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics. 2013 Aug; 23(8):383-94.
    View on PubMed
  13. Markova SM, De Marco T, Bendjilali N, Kobashigawa EA, Mefford J, Sodhi J, Le H, Zhang C, Halladay J, Rettie AE, Khojasteh C, McGlothlin D, Wu AH, Hsueh WC, Witte JS, Schwartz JB, Kroetz DL. Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther. 2013 Dec; 94(6):678-86.
    View on PubMed
  14. Tamraz B, Fukushima H, Wolfe AR, Kaspera R, Totah RA, Floyd JS, Ma B, Chu C, Marciante KD, Heckbert SR, Psaty BM, Kroetz DL, Kwok PY. OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet Genomics. 2013 Jul; 23(7):355-64.
    View on PubMed
  15. Martin MA, Kroetz DL. Abacavir pharmacogenetics--from initial reports to standard of care. Pharmacotherapy. 2013 Jul; 33(7):765-75.
    View on PubMed
  16. Lewis LD, Miller AA, Owzar K, Bies RR, Markova S, Jiang C, Kroetz DL, Egorin MJ, McLeod HL, Ratain MJ. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics. 2013 Jan; 23(1):29-33.
    View on PubMed
  17. Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013 Jan 15; 19(2):491-9.
    View on PubMed
  18. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012 Aug 22; 104(16):1264; author reply 1266-8.
    View on PubMed
  19. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res. 2012 Sep 15; 18(18):5099-109.
    View on PubMed
  20. Lee TM, Huang L, Johnson MK, Lizak P, Kroetz D, Aweeka F, Parikh S. In vitro metabolism of piperaquine is primarily mediated by CYP3A4. Xenobiotica. 2012 Nov; 42(11):1088-95.
    View on PubMed

Go to UCSF Profiles, powered by CTSI